Bone extracellular matrix proteins (Bone ECM)

The bone extracellular matrix (ECM) proteins represent the organic scaffold of bone tissue, consisting of approximately 90% Type I collagen and 10% non-collagenous proteins such as osteocalcin, osteopontin, and bone sialoprotein [Lin et al., 2020]. These proteins are essential for providing tensile strength to the skeleton and serving as a template for the deposition of hydroxyapatite crystals during mineralization [Alford et al., 2015]. Beyond structural support, the bone ECM acts as a reservoir for signaling molecules, including transforming growth factor-beta (TGF-beta) and bone morphogenetic proteins (BMPs), which regulate the activity of osteoblasts and osteoclasts [Paiva & Granjeiro, 2017]. Dysregulation of ECM protein synthesis or degradation is a hallmark of skeletal disorders such as osteoporosis, osteogenesis imperfecta, and bone metastasis [Lin et al., 2020]. Pharmacological interventions often target the turnover of these proteins; for instance, bisphosphonates bind to the mineralized ECM to inhibit bone resorption, while anabolic agents like teriparatide stimulate the production of new matrix proteins [Baron & Hesse, 2012]. Consequently, specific ECM components and their degradation products serve as critical clinical biomarkers for monitoring bone health and therapeutic efficacy [Wheater et al., 2013].

Other names

Bone matrix proteinsBone organic matrixNon-collagenous bone proteinsBone ECM proteins

Therapeutic agents interact with the bone ECM by binding to the hydroxyapatite-coated collagen fibers to prevent resorption (e.g., bisphosphonates) or by activating signaling pathways that lead to the increased secretion of collagenous and non-collagenous proteins by osteoblasts (e.g., PTH analogs) [Baron & Hesse, 2012; Lin et al., 2020].